PEAR THERAPEUTICS INC (PEAR)
US7047231052 - Common Stock
ChartMill assigns a Buy % Consensus number of 77% to PEAR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 5.44. This target is 18530.02% above the current price.
PEAR was analyzed by 12 analysts. The buy percentage consensus is at 77. So analysts seem to be have mildly positive about PEAR.
In the previous month the buy percentage consensus was at a similar level.
PEAR was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-03-20 | TD Cowen | Downgrade | Outperform -> Market Perform |
| 2023-03-20 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2023-03-20 | Credit Suisse | Downgrade | Outperform -> Neutral |
| 2022-11-16 | Citigroup | Maintains | Buy |
| 2022-11-15 | Chardan Capital | Maintains | Buy |
| 2022-11-15 | Credit Suisse | Maintains | Outperform |
| 2022-08-12 | Chardan Capital | Maintains | Buy |
| 2022-08-12 | BTIG | Maintains | Buy |
| 2022-07-26 | Credit Suisse | Maintains | Outperform |
| 2022-06-24 | BTIG | Maintains | Buy |
| 2022-05-17 | Chardan Capital | Maintains | Buy |
| 2022-05-17 | Citigroup | Maintains | Buy |
| 2022-01-26 | B of A Securities | Initiate | Neutral |
| 2022-01-20 | Credit Suisse | Initiate | Outperform |
| 2022-01-03 | BTIG | Initiate | Buy |
| 2021-12-22 | Chardan Capital | Initiate | Buy |
| 2021-12-16 | Cowen & Co. | Initiate | Outperform |